| Pharmaceutical Information |
| Drug Name |
Bretylium |
| Drug ID |
BADD_D00292 |
| Description |
Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site. |
| Indications and Usage |
For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. |
| Marketing Status |
Not Available |
| ATC Code |
Not Available |
| DrugBank ID |
DB01158
|
| KEGG ID |
Not Available
|
| MeSH ID |
C045166
|
| PubChem ID |
2431
|
| TTD Drug ID |
D02YYF
|
| NDC Product Code |
Not Available |
| Synonyms |
bretylium | bretylium chloride | bretylium iodide | bretylium bromide |
|
| Chemical Information |
| Molecular Formula |
C11H17BrN+ |
| CAS Registry Number |
59-41-6 |
| SMILES |
CC[N+](C)(C)CC1=CC=CC=C1Br |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
